These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 38141904)

  • 1. Extending Peripheral Retinal Vascularization in Retinopathy of Prematurity Through Regulation of VEGF Signaling.
    Sauer L; Chandler M; Hartnett ME
    Am J Ophthalmol; 2024 Apr; 260():190-199. PubMed ID: 38141904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of fluorescein angiographic findings in type 1 and type 2 retinopathy of prematurity with intravitreal bevacizumab monotherapy and spontaneous regression.
    Vural A; Ekinci DY; Onur IU; Hergünsel GO; Yiğit FU
    Int Ophthalmol; 2019 Oct; 39(10):2267-2274. PubMed ID: 30604251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retinal Detachment after Treatment of Retinopathy of Prematurity with Laser versus Intravitreal Anti-Vascular Endothelial Growth Factor.
    Barry GP; Yu Y; Ying GS; Tomlinson LA; Lajoie J; Fisher M; Binenbaum G;
    Ophthalmology; 2021 Aug; 128(8):1188-1196. PubMed ID: 33387554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characteristics of retinal vascularization in reactivated retinopathy of prematurity requiring treatment and clinical outcome after reinjection of ranibizumab.
    Jang JH
    Sci Rep; 2024 Jul; 14(1):15647. PubMed ID: 38977744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity.
    Sankar MJ; Sankar J; Mehta M; Bhat V; Srinivasan R
    Cochrane Database Syst Rev; 2016; 2():CD009734. PubMed ID: 26932750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity.
    Sankar MJ; Sankar J; Chandra P
    Cochrane Database Syst Rev; 2018 Jan; 1(1):CD009734. PubMed ID: 29308602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Study protocol for prognosis and treatment strategy of peripheral persistent avascular retina after intravitreal anti-VEGF therapy in retinopathy of prematurity.
    Yu Y; Wang J; Chen F; Chen W; Jiang N; Xiang D
    Trials; 2020 Jun; 21(1):493. PubMed ID: 32513245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of intravitreal bevacizumab for zone-II retinopathy of prematurity.
    Karkhaneh R; Khodabande A; Riazi-Eafahani M; Roohipoor R; Ghassemi F; Imani M; Dastjani Farahani A; Ebrahimi Adib N; Torabi H
    Acta Ophthalmol; 2016 Sep; 94(6):e417-20. PubMed ID: 27009449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Management of Recurrent Retinopathy of Prematurity after Intravitreal Bevacizumab Monotherapy.
    Mintz-Hittner HA; Geloneck MM; Chuang AZ
    Ophthalmology; 2016 Sep; 123(9):1845-55. PubMed ID: 27241619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reactivation of retinopathy of prematurity after ranibizumab treatment.
    Wong RK; Hubschman S; Tsui I
    Retina; 2015 Apr; 35(4):675-80. PubMed ID: 25768252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reactivation of retinopathy of prematurity six years after intravitreal injection of bevacizumab.
    Yasin A; Sinha S; Smith R; Jain SF; Hejkal T; Rychwalski P
    J AAPOS; 2023 Aug; 27(4):236-239. PubMed ID: 37451499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Effect of Intravitreal Bevacizumab Dose on Retinal Vascular Progression in Retinopathy of Prematurity.
    Bayramoglu SE; Sayin N
    Ophthalmologica; 2022; 245(2):161-172. PubMed ID: 34844257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined Vitrectomy and Anti-VEGF Treatment for Stage 4 Retinopathy of Prematurity With Extensive Neovascular Proliferation.
    Chandra P; Kumawat D; Agarwal D; Chawla R
    J Pediatr Ophthalmol Strabismus; 2020 Jan; 57(1):61-66. PubMed ID: 31972043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison in Retreatments between Bevacizumab and Ranibizumab Intravitreal Injections for Retinopathy of Prematurity: A Multicenter Study.
    Patel NA; Acaba-Berrocal LA; Hoyek S; Fan KC; Martinez-Castellanos MA; Baumal CR; Harper CA; Berrocal AM;
    Ophthalmology; 2023 Apr; 130(4):373-378. PubMed ID: 36396121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of optical coherence tomography biomarkers to differentiate favourable and unfavourable responders to intravitreal anti-vascular endothelial growth factor treatment in retinopathy of prematurity.
    Belenje A; Reddy RU; Parmeswarappa DC; Padhi TR; Subbarao B; Jalali S
    Eye (Lond); 2024 Apr; 38(6):1097-1103. PubMed ID: 37968517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravitreal Bevacizumab for Zone II Retinopathy of Prematurity.
    Larrañaga-Fragoso P; Peralta J; Bravo-Ljubetic L; Pastora N; Abelairas-Gómez J
    J Pediatr Ophthalmol Strabismus; 2016 Nov; 53(6):375-382. PubMed ID: 27537247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Fluorescein Angiography Findings in Stage 3 Retinopathy of Prematurity in Zone II Treated With or Without Anti-VEGF.
    Vural A; Demirayak B; Ozbas M; Onur IU; Celik G
    Eur J Ophthalmol; 2022 Nov; 32(6):3281-3288. PubMed ID: 35191353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma Levels of Bevacizumab and Vascular Endothelial Growth Factor After Low-Dose Bevacizumab Treatment for Retinopathy of Prematurity in Infants.
    ; Hartnett ME; Wallace DK; Dean TW; Li Z; Boente CS; Dosunmu EO; Freedman SF; Golden RP; Kong L; Prakalapakorn SG; Repka MX; Smith LE; Wang H; Kraker RT; Cotter SA; Holmes JM
    JAMA Ophthalmol; 2022 Apr; 140(4):337-344. PubMed ID: 35446359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Dosing Study of Bevacizumab for Retinopathy of Prematurity: Late Recurrences and Additional Treatments.
    Wallace DK; Dean TW; Hartnett ME; Kong L; Smith LE; Hubbard GB; McGregor ML; Jordan CO; Mantagos IS; Bell EF; Kraker RT;
    Ophthalmology; 2018 Dec; 125(12):1961-1966. PubMed ID: 29887334
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effects of intravitreal pegaptanib or bevacizumab and laser in treatment of threshold retinopathy of prematurity in zone I and posterior zone II--four years results].
    Autrata R; Senková K; Holousová M; Krejcírová I; Dolezel Z; Borek I
    Cesk Slov Oftalmol; 2012 Feb; 68(1):29-36. PubMed ID: 22679695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.